Gly-Phe-amid | 89460-16-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Gly-Phe-amid
• 英文别名: N-glycyl-DL-phenylalanine amide；N-Glycyl-DL-phenylalanin-amid；Glycyl-D-phenylalaninamide；2-[(2-aminoacetyl)amino]-3-phenylpropanamide
• CAS: 89460-16-2
• 化学式: C₁₁H₁₅N₃O₂
• 分子量: 221.259
• InChiKey: PSPZOKPNYCSKSW-UHFFFAOYSA-N

物化性质

• 沸点：
  540.6±50.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  98.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 甲醇 、 palladium on activated charcoal 、 溶剂黄146 作用下， 生成 Gly-Phe-amid
  参考文献：
  名称：

  The Formation of Diketopiperazines from Dipeptide Amides^1a

  摘要：

  DOI：

  10.1021/ja01158a072

文献信息

• Method for measurement of trace enzymes
  申请人：FUJI PHOTO FILM CO., LTD.

  公开号：EP0048834A1

  公开（公告）日：1982-04-07

  The amount of enzyme is determined by reacting an enzyme to be measured with a synthetic substrate having at least one structure to be specifically contacted with the enzyme and at least one spectral sensitizer structure, bringing either the reaction product having the spectral sensitizer structure or the unreacted synthetic substrate into contact with a silver halide emulsion layer, exposing the same to light of a spectral sensitizing wavelength region corresponding to the spectral sensitizer structure, developing the silver halide, and then measuring the optical density of developed silver and/or colored dye.

  酶量的测定方法是：将待测酶与具有至少一种与酶特异性接触的结构和至少一种光谱增感剂结构的合成底物反应，使具有光谱增感剂结构的反应产物或未反应的合成底物与卤化银乳剂层接触，将其暴露于与光谱增感剂结构相对应的光谱增感波长区域的光下，显影卤化银，然后测量显影银和/或有色染料的光密度。
• Verfahren zur Herstellung von Additionsverbindungen aus Dipeptiden und Aminen
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0201855A2

  公开（公告）日：1986-11-20

  Das Dipeptid aus einer N-geschützten L-Asparaginsäure und L-Phenylalaninmethylester bildet mit Aminen schwer lösliche Additionsverbindungen, die sich leicht aus dem Reaktionsmedium abtrennen lassen.

  N 保护的 L-天冬氨酸和 L-苯丙氨酸甲酯二肽与胺形成难溶的加成化合物，很容易从反应介质中分离出来。
• Capillary tube with reduced protein interactions and controllable electroosmotic flow
  申请人：Hewlett-Packard Company

  公开号：EP0354984A2

  公开（公告）日：1990-02-21

  A method for treating capillary walls exposable to protein solutes is provided that reduces interactions of the protein solutes with the wall and that permits control of electroosmotic flow within the capillaries by selection of solution pH. Thus, a capillary tube has an interfacial layer covalently bonded to the inner wall of the tube. This interfacial layer is effective to reduce interactions between the inner wall and protein solutes and preferably includes a hydratable amphoteric phase. The amphoteric phase is a reaction product of a protein, peptide or an ampholyte and an oxygen or nitrogen nucleophile. Electroosmotic flow magnitude and/or flow direction may be controlled when capillaries of the invention are used for electrophoretic separations.

  提供了一种处理可接触蛋白质溶质的毛细管壁的方法，这种方法可减少蛋白质溶质与管壁的相互作用，并可通过选择溶液的 pH 值来控制毛细管内的电渗流。因此，毛细管的内壁上有一层共价键结合的界面层。该界面层可有效减少内壁与蛋白质溶质之间的相互作用，最好包括可水合的两性相。两性相是蛋白质、肽或两性溶解物与氧或氮亲核物的反应产物。当本发明的毛细管用于电泳分离时，可控制电渗流的大小和/或流动方向。
• LOW-MOLECULAR POLYSULFATED HYALURONIC ACID DERIVATIVE AND MEDICINE CONTAINING SAME
  申请人：Otsuka Chemical Holdings Co., Ltd.

  公开号：EP2392579A1

  公开（公告）日：2011-12-07

  A low-molecular-weight polysulfated hyaluronic acid derivative useful for prevention and/or treatment of an allergic disease. An agent for prevention and/or treatment of an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, and asthma, represented by the following general formula (IA) or (IB); wherein n represents a number of 0 to 15; R's each independently represent a hydrogen atom or an SO3H group etc.

  一种用于预防和/或治疗过敏性疾病的低分子量多硫化透明质酸衍生物。一种用于预防和/或治疗选自花粉症、过敏性鼻炎、过敏性结膜炎、特应性皮炎和哮喘的过敏性疾病的制剂，由以下通式（IA）或（IB）表示； 其中 n 代表 0 至 15 的数字；R's 各自独立地代表氢原子或 SO3H 基团等。
• ANTIBODY-DRUG CONJUGATE PRODUCED BY BINDING THROUGH LINKER HAVING HYDROPHILIC STRUCTURE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2910573A1

  公开（公告）日：2015-08-26

  As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH-(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.

  作为一种抗肿瘤效果和安全性俱佳的抗肿瘤药物，本发明提供了一种抗体-药物共轭物，其中下式（I）表示的抗肿瘤化合物通过具有下式表示的结构的连接体与抗体共轭：-L1-L2-LP-NH-(CH2)n1-La-Lb-Lc-或-L1-L2-LP-，其中抗体连接到 L1 的末端，抗肿瘤化合物连接到 Lc 或 LP 的末端，并且 L1、L2 和 LP 中的任意一个或两个或多个连接体具有亲水结构。